Skip to main content
. 2019 Nov 25;3(22):3700–3708. doi: 10.1182/bloodadvances.2019000655

Table 3.

Development of tuberculosis, herpes zoster, and lymphoma according to ruxolitinib exposure in patients with MF

N PMF: SMF Male: female Follow-up duration, median (range), mo No. of patients with tuberculosis* No. of patients with herpes zoster* No. of patients with lymphoma*
Patients exposed to ruxolitinib 192 161:31 125:67 16.2 (1.0-28.8) 5 (2.6%) 22 (11.5%) 1 (0.5%)
2 male subjects and 3 female subjects 13 male subjects and 9 female subjects A 54-year-old female patient
Median age, 68 y (range, 44-77 y) Median age, 66.5 y (range, 40-86 y) Diagnosed with B-cell non-Hodgkin lymphoma
Median time from ruxolitinib to tuberculosis, 12.9 mo (range, 1.34-16.38 mo) Median time from ruxolitinib to herpes zoster, 6.92 mo (range, 0-23.55 mo) Time from ruxolitinib to diagnosis of lymphoma, 6.2 mo
Patients not exposed to ruxolitinib 489 433:56 292:197 28.78 (1-113.8) 11 (2.3%) 40 (8.2%) 4 (0.8%)
10 male subjects and 1 female subject 26 male subjects and 14 female subjects 3 male subjects and 1 female
Median age, 76 y (range, 66-87 y) Median age, 63 y (range, 27-83) Median age: 71.5 y (range, 54-75 y)
Median time from diagnosis of MF to tuberculosis, 19.9 mo (range, 2.3-88.5 mo) Median time from diagnosis of MF to herpes zoster: 18.8 mo (range, 1.74-81.6 mo) Median time from diagnosis of MF to lymphoma, 25.7 mo (range, 6.0-54.6 mo)
*

From 1 month after initiation of ruxolitinib (in ruxolitinib-exposed patients) or diagnosis of MF (in the ruxolitinib-nonexposed patients) to last follow-up or death.

From initiation of ruxolitinib to last follow-up or death.

From diagnosis of PMF or SMF to last follow-up or death.